BioWorld

Dec. 28, 2006

CombiMatrix Breaks From Acacia, To List On AMEX

Biotech tools company CombiMatrix Corp. has filed to list its stock on the American Stock Exchange in a move to separate itself from parent Acacia Research Corp. (BioWorld Today) Read More

AstraZeneca Goes Forward With AZD3480; Targacept Gets $20M

Fighting 'Gang Of Four' Is Uphill Battle, But Success Stories Exist

Placement Gives Callisto Funds For Clinical-Stage Cancer Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 20, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

Novel caspase-2 inhibitor shows in vivo neuroprotective effects

BioWorld Science

Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...